These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1582287)

  • 1. Perspective: preventive isoniazid therapy and the liver.
    Israel HL; Gottlieb JE; Maddrey WC
    Chest; 1992 May; 101(5):1298-301. PubMed ID: 1582287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older. A prospective analysis.
    Sorresso DJ; Mehta JB; Harvill LM; Bentley S
    Chest; 1995 Sep; 108(3):706-11. PubMed ID: 7656620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Close monitoring is essential during isoniazid prophylaxis.
    Atuk NO; Hart AD; Hunt EH
    South Med J; 1977 Feb; 70(2):156-9. PubMed ID: 841390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current changes in the recommendations for INH preventive treatment of tuberculous infection in Alabama.
    J Med Assoc State Ala; 1974 Sep; 44(3):140-1. PubMed ID: 4419724
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
    Bray MG; Poulain C; Dougados M; Gossec L
    Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
    Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
    Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender.
    Jordan TJ; Lewit EM; Reichman LB
    Am Rev Respir Dis; 1991 Dec; 144(6):1357-60. PubMed ID: 1741549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How safe is isoniazid?
    Thompson JE
    Med J Aust; 1978 Feb; 1(3):165-9. PubMed ID: 651734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid liver injury during chemoprophylaxis in children.
    Spyridis P; Sinaniotis C; Papadea I; Oreopoulos L; Hadjiyiannis S; Papadatos C
    Arch Dis Child; 1979 Jan; 54(1):65-7. PubMed ID: 420524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid hepatitis in adolescents.
    Litt IF; Cohen MI; McNamara H
    J Pediatr; 1976 Jul; 89(1):133-5. PubMed ID: 819639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe isoniazid-associated hepatitis--New York, 1991-1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Jul; 42(28):545-7. PubMed ID: 8326947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid].
    Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
    Kekkaku; 2007 Jan; 82(1):1-9. PubMed ID: 17310776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.
    International Union Against Tuberculosis Committee on Prophylaxis
    Bull World Health Organ; 1982; 60(4):555-64. PubMed ID: 6754120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid-associated hepatitis--serum enzyme determinations and histologic features.
    Lewis JE; Mello P; Knauer CM
    West J Med; 1975 May; 122(5):371-6. PubMed ID: 1130028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
    Kopanoff DE; Snider DE; Caras GJ
    Am Rev Respir Dis; 1978 Jun; 117(6):991-1001. PubMed ID: 666111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid-related hepatitis.
    Vasudeva R; Woods B
    Dig Dis; 1997; 15(6):357-67. PubMed ID: 9439900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.